--- title: Advancing Biomarker Discovery for Disease Insights - Symposium Highlights description: Highlights from Scientist’s biomarker symposium - AI and proteomics trends, plus how Aviva’s antibody-to-assay workflow supports assay readiness in matrices. image: https://blog.avivasysbio.com/hubfs/biomarker%20symposium%20cover%20blk.png --- ![](https://blog.avivasysbio.com/hs-fs/hubfs/biomarker%20symposium%20cover%20blk.png?width=4034&height=2561&name=biomarker%20symposium%20cover%20blk.png) Webinars # Advancing Biomarker Discovery for Disease Insights - Symposium Highlights ![Aviva Systems Biology](https://blog.avivasysbio.com/hs-fs/hubfs/aviva_systems_biology_logo_rgb%20-%20Copy.png?width=48&height=48&name=aviva_systems_biology_logo_rgb%20-%20Copy.png) Aviva Systems Biology February 25, 2026 Advancing Biomarker Discovery for Disease Insights - Symposium Highlights 4:22 Biomarker discovery is moving quickly. Proteomic profiling, AI-driven analytics, and more accessible multi-omics are helping teams nominate targets faster and connect signals to disease mechanisms. The symposium made one point especially clear, though: discovery only creates value when the biomarker can be measured reliably across real samples and real workflows.  [Watch the Symposium](https://youtu.be/Sk7ma0nbSv4)   Aviva sponsored this symposium, *Advancing Biomarker Discovery for Disease Insights* to spotlight both emerging discovery methods and the practical realities of translating biomarkers into dependable measurements. Here are some of our takeaways:  **1) Discovery is accelerating - but translation still hinges on measurement** Across talks, the common friction point was reproducibility: signals that look compelling in early datasets can become difficult to confirm across cohorts, sites, and platforms. The limiting factor is often not biological relevance - it is whether the assay can deliver consistent performance in the intended sample type. *Practical takeaway* Define your measurement path early: sample type (CSF, serum, plasma, tissue), expected abundance, dynamic range, and the decision the biomarker must support. **2) Multi-modal data raises the bar for assay specificity and controls** As teams integrate proteomics, genomics, imaging, and orthogonal validation, false positives scale faster. Multi-modal workflows increase the need for reagent specificity, well-designed controls, and clearly understood failure modes, especially when moving from clean systems into complex matrices. *Practical takeaway* Plan orthogonal validation up front, and choose controls that test specificity in a meaningful context for your matrix and intended use. **3) “Actionable” biomarkers require assay readiness sooner than most teams expect** The most advanced programs treat assay planning as part of discovery, not a downstream cleanup step. Whether the endpoint is research use, clinical feasibility, or therapeutic monitoring, early assay readiness questions reduce rework later. *Practical takeaway* If your biomarker is moving toward translation, start asking now: sensitivity requirements, matrix effects, interference risk, scalability, and how performance will be verified over time. **What Aviva presented - building assay-ready antibody pairs for biomarker studies** In her session, April Livengood, PhD (Director of Strategic Business Development & Collaborations) focused on what matters most for antibody selection and assay performance in real sample matrices. (See us on [LinkedIn](https://www.linkedin.com/company/aviva-systems-biology)) [![Thumbnail TS symposium talk](https://blog.avivasysbio.com/hs-fs/hubfs/Thumbnail%20TS%20symposium%20talk.png?width=1875&height=1026&name=Thumbnail%20TS%20symposium%20talk.png)](https://youtu.be/Y9p_M0GhEoA)A core theme was that “antibody-to-assay” workflows work best when they are designed to reduce downstream risk - by generating options early, measuring binding behavior quantitatively, and pressure-testing performance in the matrices that will matter later. **Aviva’s workflow - from antibody discovery to matrix-tested assay candidates** Our recombinant immunoassay workflow starts with high-throughput antibody discovery and progresses through quantitative screening and functional pair testing, with decision points designed to preserve optionality and avoid single-clone failure. Key elements include: **Example from our progranulin case study:** Hundreds of recombinant clones were characterized (including affinity, specificity, and epitope diversity), top candidates were tested as ELISA pairs, and the optimized assay was evaluated in human serum and CSF. **How Aviva supports biomarker measurement** Aviva supports biomarker teams with both research-grade tools and custom capabilities that help bridge discovery and measurement - especially when programs are moving into complex matrices or higher-confidence workflows. If you are evaluating a biomarker target and want to sanity check assay feasibility, please email us at [info@avivasysbio.com](mailto:info@avivasys) or [techsupport@avivasysbio.com](mailto:techsupport@avivasysbio.com) and share: We will point you to the most relevant next resource - including on-demand symposium materials, posters, case studies, or a short technical discussion with our team. ## Share this post [mailto:https%3A%2F%2Fblog.avivasysbio.com%2Fadvancing-biomarker-discovery-for-disease-insights-symposium-highlights](mailto:https%3A%2F%2Fblog.avivasysbio.com%2Fadvancing-biomarker-discovery-for-disease-insights-symposium-highlights) ## Keep reading [![](https://blog.avivasysbio.com/hs-fs/hubfs/Depositphotos_73135721_XL-2.jpg?width=6750&height=4500&name=Depositphotos_73135721_XL-2.jpg) Antibody Education ### Why KO Validation Strengthens Polyclonal Antibody Data ](https://blog.avivasysbio.com/why-ko-validation-strengthens-polyclonal-antibody-data) [![](https://blog.avivasysbio.com/hs-fs/hubfs/Western%20Blot.jpg?width=4000&height=2250&name=Western%20Blot.jpg) Technical Support ### 5 Factors That Improve FTO Western Blot Consistency ](https://blog.avivasysbio.com/5-factors-that-improve-fto-western-blot-consistency) ```json { "@context" : "https://schema.org", "@type" : "BlogPosting", "author" : { "@type" : "Person", "name" : "Aviva Systems Biology", "url" : "https://blog.avivasysbio.com/author/aviva-systems-biology" }, "dateModified" : "2026-03-24T21:25:41.287Z", "datePublished" : "2026-02-25T16:00:00.000Z", "headline" : "Advancing Biomarker Discovery for Disease Insights - Symposium Highlights", "image" : [ "https://blog.avivasysbio.com/hubfs/biomarker%20symposium%20cover%20blk.png" ], "mainEntityOfPage" : { "@id" : "https://blog.avivasysbio.com/advancing-biomarker-discovery-for-disease-insights-symposium-highlights", "@type" : "WebPage" }, "publisher" : { "@type" : "Organization", "logo" : { "@type" : "ImageObject", "url" : "https://blog.avivasysbio.com/hubfs/tiny_aviva_systems_biology_logo_rgb_resize-1.png" }, "name" : "Aviva Systems Biology" } } ```